Agnete Kirkeby

High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO) (2008)

Kirkeby, Agnete, Torup, Lars, Bochsen, Louise, Kjalke, Marianne, Abel, Kristin, Theilgaard-Monch, Kim, ...

The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose...

The biological and ethical basis of the use of human embryonic stem cells for in vitro test systems or cell therapy (2008)

Leist, Marcel, Bremer, Susanne, Brundin, Patrik, Hescheler, Jürgen, Kirkeby, Agnete, Krause, Karl-Heinz, ...

Human embryonic stem cells (hESC) are now routinely cultured in many laboratories, and differentiation protocols are available to generate a large variety of cell types. In an ongoing ethical debate...

Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor (2007)

Kirkeby, Agnete, Beek, Johan Van, Nielsen, Jacob, Leist, Marcel, Helboe, Lone

Since it was discovered that the hematopoietic hormone erythropoetin (EPO) exerts neuroprotective effects in the CNS, many studies on the EPO receptor (EPOR) function and localisation in the CNS have...

Comparison of neuroprotective effects of erythropoietin (EPO) and carbamylerythropoietin (CEPO) against ischemia-like oxygen–glucose deprivation (OGD) and NMDA excitotoxicity in mouse hippocampal slice cultures (2006)

Montero, Maria, Rom Poulsen, Frantz, Noraberg, Jens, Kirkeby, Agnete, Beek, Johan Van, Leist, Marcel, ...

In addition to its well-known hematopoietic effects, erythropoietin (EPO) also has neuroprotective properties. However, hematopoietic side effects are unwanted for neuroprotection, underlining the...